Coegin Pharma delivers first commercial batch of Follicopeptide products to Gents

Coegin Pharma AB ("Coegin" or the "Company") today announces that the Company has successfully produced and delivered its first commercial batch of hair growth products based on Follicopeptide^® to Gents, one of the leading premium grooming retailers in the Nordic region.                                                                                                       

The delivered batch is intended for customers who placed pre-orders with Gents' mid November. The entire pre-order batch sold out in just a couple of days, clearly demonstrating strong consumer interest ahead of the full market launch. Following this successful pre-launch, a broader commercial roll-out together with Gents is planned to take place towards the end of January 2026.

The production and delivery of the first commercial batch represent a major milestone for Coegin and a clear proof of the Company's transition from development to commercial operations. It confirms that Coegin's technology, production setup, and supply chain are now fully operational at commercial scale.

"This is an important and very gratifying milestone for Coegin," says Jens Eriksson, CEO of Coegin Pharma. Delivering our first commercial batch to Gents shows that we are now executing on our strategy, turning strong science into market-ready products. Selling out the entire pre-order batch within days is a powerful validation of both the product and the demand we are seeing. With additional deliveries already lined up, we are well positioned to accelerate our commercial roll-out."

In parallel, commercial momentum continues to build. The Company expects its next delivery to take place already next week, to Hårklinikken, further strengthening Coegin's presence in professional and premium distribution channels. 

"We now have a validated product, an industrialized production process, and an expanding partner network. This places Coegin in a strong position as we move into the next phase of growth," Eriksson adds.

Coegin continues to work actively with both existing and potential partners across selected markets, with the ambition to establish Follicopeptide as a leading science-based solution in premium hair growth segment.

For further information, please contact:
Jens Eriksson, CEO, Coegin Pharma AB
Email: [email protected]

About Coegin Pharma
Coegin Pharma is a Swedish biotech company with cutting-edge innovations for hair and skin. The company is currently commercializing its patented hair growth innovation Follicopeptide® on a global scale. In development is NPP-4, a next-generation peptide that represents a novel approach to regulating skin pigmentation through advanced biotechnology.

Coegin Pharma's share is listed on NGM Nordic SME and dual-listed on Börse Stuttgart. The company is headquartered in Lund, Sweden.

More information - including subscription to company updates and links to social media - is available at coeginpharma.com